文献速递淋巴瘤

CD20抗体与激酶抑制剂对慢性淋巴细胞白血病B细胞受体信号及存活的影响

Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells.
PubMed 文献 · Br J Haematol · 2020-11-20

本研究利用磷酸化特异性流式细胞术,检测CD20治疗抗体(利妥昔单抗、奥法木单抗、奥妥珠单抗)及B细胞受体相关激酶抑制剂(ibrutinib、idelalisib)对慢性淋巴细胞白血病(CLL)患者白血病细胞B细胞受体信号通路和存活的影响。结果显示CD20抗体优先抑制pBTKY551而非BTKY223及pAKT,而激酶抑制剂对pBTKY223的抑制强于pBTKY551;CD20抗体与激酶抑制剂联合可显著增强白血病细胞死亡,且联合增强效应约为相加作用。

要点

  • CD20抗体优先抑制CLL细胞pBTKY551而非BTKY223及pAKT。
  • Ibrutinib和idelalisib对pBTKY223抑制强于pBTKY551。
  • CD20抗体与BAKi联合增强CLL细胞死亡,效应约相加。

核心结论

  • CD20单抗及其与B细胞受体相关激酶抑制剂的联合对CLL的B细胞受体信号和细胞存活具有负调控效应。

研究设计与样本

  • 采用磷酸化特异性流式细胞术,检测CLL患者白血病细胞在CD20治疗抗体及B细胞受体相关激酶抑制剂作用下的信号通路与存活变化。

主要发现

  • 利妥昔单抗、奥法木单抗和奥妥珠单抗优先抑制pBTKY551而非BTKY223,并抑制pAKT。
  • Ibrutinib和idelalisib对pBTKY223的抑制程度高于pBTKY551。
  • Idelalisib联合利妥昔单抗或奥法木单抗可增强对pAKT的抑制。
  • CD20单抗与BAKi联合诱导白血病细胞死亡,增强效应约为相加作用。

临床怎么用

  • 研究提示CD20单抗与BAKi联合在CLL治疗中具有潜在协同作用,可为临床试验联合方案提供机制依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recently, clinical trial results have established inhibitors of B-cell receptor (BCR)-associated kinase (BAKi), with or without CD20 moniclonal antibodies (mAbs), as the preferred first-line treatment for most chronic lymphocytic leukaemia (CLL) patients. Using phosphospecific flow cytometry, we showed that in leukaemic cells from CLL patients the CD20 therapeutic antibodies - rituximab, ofatumumab, and obinutuzumab - inhibited BCR signalling pathways targeting preferentially pBTKY551 - but not BTKY223 - and pAKT. On the contrary, ibrutinib and idelalisib reduced pBTKY223 to a higher extent than pBTKY551 . The strong reduction of pAKT induced by idelalisib was enhanced by its combination with rituximab or ofatumumab. Moreover, CD20 mAbs and BAKi induced the death of leukaemia cells that was significantly potentiated by their combination. Analysis of the enhancement of cell death in these combinations revealed an approximately additive enhancement induced by rituximab or obinutuzumab combined with ibrutinib or idelalisib. Taken together, our data identified negative regulatory effects of CD20 mAbs and their combinations with BAKi on BCR signalling and cell survival in CLL. In conclusion, this study advances our understanding of mechanisms of action of CD20 mAbs as single agents or in combination with BAKi and could inform on the potential of combined therapies in ongoing and future clinical trials in patients with CLL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Cavallini C, Galasso M, Pozza ED, et al. Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells. Br J Haematol. 2020. PMID: 33216963. doi:10.1111/bjh.17139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。